Walter Public Investments Inc. Acquires 10,920 Shares of Novo Nordisk A/S (NYSE:NVO)

Walter Public Investments Inc. raised its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 5.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 209,977 shares of the company's stock after acquiring an additional 10,920 shares during the quarter. Novo Nordisk A/S comprises approximately 2.7% of Walter Public Investments Inc.'s investment portfolio, making the stock its 18th biggest holding. Walter Public Investments Inc.'s holdings in Novo Nordisk A/S were worth $14,581,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVO. Strategic Investment Solutions Inc. IL boosted its stake in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the last quarter. Copeland Capital Management LLC increased its position in shares of Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after buying an additional 255 shares in the last quarter. North Capital Inc. bought a new position in Novo Nordisk A/S during the 1st quarter worth about $27,000. Park Square Financial Group LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth about $29,000. Finally, Transce3nd LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth about $33,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 0.4%

Shares of Novo Nordisk A/S stock traded up $0.31 during trading on Tuesday, hitting $69.63. The company's stock had a trading volume of 9,838,730 shares, compared to its average volume of 7,271,481. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $143.69. The stock has a market cap of $310.90 billion, a price-to-earnings ratio of 20.60, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64. The stock has a 50-day moving average price of $70.10 and a two-hundred day moving average price of $75.41.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The company had revenue of $11.87 billion for the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Ratings Changes

NVO has been the subject of a number of recent research reports. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating on the stock. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Finally, Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.